Competitor Landscape: Graft Versus Host Disease (GVHD)
Summary "Competitor Landscape: Graft Versus Host Disease (GVHD)", briefings contain evaluations of ongoing development activities within the GVHD market, together with analysis of current & potential future product positioning.
Key Highlights from the report - - Anticipated approval of ATIR101 is delayed both in the EU and US - with the postponed primary completion date in the ongoing Phase III trial delaying the expected US approval by 9 months - If approved, Ruxolitinib for use in combination with corticosteroids for the treatment of steroid-refractory aGVHD would make it the second drug to receive US approval for the treatment of GVHD after Janssen/AbbVie’s IBR - Incyte has not only delayed the initiation of Itacitinib’s GRAVITAS-309 trial, but significantly extended its duration (from ~2.5 years to ~4.5 years)
The report comprises four key sections.
Executive Summary: Contains analysis of key market events that have occurred during the period 10 August 2018 - 10 November 2018 which have impacted the GVHD landscape
Landscape Updates: Section contains the following analysis - - ‘Order of Entry’ analysis, containing detailed timeline forecasts for each drug in Phase II development or higher, and timeline forecasts for each approved product’s lifecycle management initiatives. - ‘Direction of Travel’ analysis for currently approved therapies, together with an assessment of initial market entry strategies for key pipeline candidates.
Approved & Pipeline Product Landscape: Section contains the following analysis - - An overview of pipeline & approved products, containing snapshots of current development status - Expected drug-specific events & milestones until YE 2020
Appendix: Data slides containing the following information - - Current Early Stage GVHD Pipeline & candidate ‘Watch List’. - Timeline Assumptions, including standard assumptions & drug-specific assumptions.
Scope - The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov) - Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix - Forecasts are presented in pipeline forecast figures & detailed tables - ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy - Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher - Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market - Reviews ongoing lifecycle management strategies for existing players in the market - A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Our reports have been used by over 10K customers, including:
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
120 pages •
By Infiniti Research Limited
• Feb 2021
Global Mycosis Fungoides Therapeutics Market 2021-2025 The analyst has been monitoring the mycosis fungoides therapeutics market and it is poised to grow by $ 115.42 mn during 2021-2025, progressing at a CAGR of 5% during the forecast period. Our report on mycosis fungoides therapeutics market provides a holistic analysis,...
376 pages •
By Global Industry Analysts
• Mar 2021
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 5
- Influencer Pool: 836
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
“LONCASTUXIMAB TESIRINE- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse large B cell lymphoma in 7 Major Markets. A detailed picture of the LONCASTUXIMAB TESIRINE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United...
Anti-Viral Therapeutics Market Report Overview Anti-Viral Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Anti-Viral Therapeutics market types and applications. It is a focused study on Anti-Viral Therapeutics market space...
Hereditary Angioedema Therapeutics Market Report Overview Hereditary Angioedema Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Hereditary Angioedema Therapeutics market types and applications. It is a focused study on...
“Phesgo - Drug Insight and Market Forecast - 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Phesgo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
242 pages •
By The Business Research Company
• Dec 2020
CAR-T Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global CAR-T Therapy market. Description: Where is the largest and fastest growing market for the CAR-T therapy...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.